Nektar Therapeutics Impairment of Long-Lived Assets Held-for-use
Nektar Therapeutics (NKTR) reported Impairment of Long-Lived Assets Held-for-use of $4.44 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-03-13
- Nektar Therapeutics impairment of long-lived assets held-for-use for the quarter ending 2025-12-31 was $4.44M.
- Nektar Therapeutics impairment of long-lived assets held-for-use for the quarter ending 2025-09-30 was $0.00.
- Nektar Therapeutics impairment of long-lived assets held-for-use for the quarter ending 2024-12-31 was $0.00.
- Nektar Therapeutics impairment of long-lived assets held-for-use for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics impairment of long-lived assets held-for-use for fiscal 2025 was $4.44M, a 46.68% decline from fiscal 2024.
- Nektar Therapeutics impairment of long-lived assets held-for-use for fiscal 2024 was $8.33M, a 76.42% decline from fiscal 2023.
- Nektar Therapeutics impairment of long-lived assets held-for-use for fiscal 2023 was $35.33M, a 46.28% decline from fiscal 2022.
- Nektar Therapeutics impairment of long-lived assets held-for-use for fiscal 2022 was $65.76M.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 3 month as first filed | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 6 month as first filed | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 9 month as first filed | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $4.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $4.44M derived: sum of 2 quarters · filed 2026-03-13 | $4.44M 10-K · filed 2026-03-13 | ||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | |||||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-08 | ||||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-13 | $8.33M derived: sum of 3 quarters · filed 2026-03-13 | $8.33M 10-K · filed 2026-03-13 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-08 | $8.33M derived: sum of 2 quarters · filed 2025-08-08 | $8.33M 10-Q · filed 2025-11-07 | $7.03M derived: sum of 4 quarters · filed 2025-08-08 | |||
| 2024-06-30 | $8.33M 10-Q · filed 2025-08-08 | $8.33M 10-Q · filed 2025-08-08 | $7.03M derived: sum of 3 quarters · filed 2025-08-08 | $17.20M derived: sum of 4 quarters · filed 2025-08-08 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-10 | -$1.30M derived: sum of 2 quarters · filed 2025-03-14 | $8.87M derived: sum of 3 quarters · filed 2025-03-14 | $22.13M derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2023-12-31 | -$1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $8.87M derived: sum of 2 quarters · filed 2025-03-14 | $22.13M derived: sum of 3 quarters · filed 2025-03-14 | $35.33M 10-K · filed 2025-03-14 | |||
| 2023-09-30 | $10.17M 10-Q · filed 2024-11-08 | $23.43M derived: sum of 2 quarters · filed 2024-11-08 | $36.63M 10-Q · filed 2024-11-08 | $43.87M derived: sum of 4 quarters · filed 2024-11-08 | |||
| 2023-06-30 | $13.26M 10-Q · filed 2024-08-09 | $13.30M 10-Q · filed 2023-08-09 | $26.45M 10-Q · filed 2024-08-09 | $33.70M derived: sum of 3 quarters · filed 2024-08-09 | $34.90M derived: sum of 4 quarters · filed 2024-08-09 | ||
| 2023-03-31 | $13.20M 10-Q · filed 2024-05-10 | $20.44M derived: sum of 2 quarters · filed 2024-05-10 | $21.64M derived: sum of 3 quarters · filed 2024-05-10 | $78.96M derived: sum of 4 quarters · filed 2024-05-10 | |||
| 2022-12-31 | $7.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $8.44M derived: sum of 2 quarters · filed 2024-03-05 | $65.76M derived: sum of 3 quarters · filed 2024-03-05 | $65.76M 10-K · filed 2024-03-05 | |||
| 2022-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $58.52M derived: sum of 2 quarters · filed 2023-11-08 | $58.52M 10-Q · filed 2023-11-08 | $5.12M 10-Q · filed 2022-11-04 | |||
| 2022-06-30 | $57.32M 10-Q · filed 2023-08-09 | $57.32M 10-Q · filed 2023-08-09 | $5.12M 10-Q · filed 2022-08-05 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | ||||||
| 2021-12-31 | $0.00 10-K · filed 2024-03-05 | ||||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $0.00 derived: sum of 2 quarters · filed 2015-02-26 | $0.00 derived: sum of 3 quarters · filed 2015-02-26 | $1.68M 10-K · filed 2015-02-26 | |||
| 2012-09-30 | $0.00 10-Q · filed 2012-11-09 | $0.00 derived: sum of 2 quarters · filed 2012-11-09 | $1.68M 10-Q · filed 2013-11-07 | ||||
| 2012-06-30 | $0.00 10-Q · filed 2012-11-09 | $1.68M 10-Q · filed 2013-08-09 | |||||
| 2012-03-31 | $1.68M 10-Q · filed 2013-05-09 | ||||||
| 2011-12-31 | $0.00 10-K · filed 2012-02-29 | ||||||
| 2010-12-31 | $12.58M 10-K · filed 2012-02-29 | $12.58M 10-K · filed 2013-03-01 | |||||
| 2009-12-31 | $0.00 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |